<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Less than 1% of patients with the <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (APS) can develop multiple, simultaneous organ-system <z:hpo ids='HP_0001907'>thromboembolic disease</z:hpo>, which is referred to as the catastrophic <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome (CAPS) </plain></SENT>
<SENT sid="1" pm="."><plain>Roughly one-half of these patients have <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
<SENT sid="2" pm="."><plain>Factors known to precipitate CAPS include <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, surgery, trauma, <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, anticoagulation withdrawal, obstetric complications, and SLE flares </plain></SENT>
<SENT sid="3" pm="."><plain>Optimal treatment includes anticoagulation and high-dose <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, although IVIG and plasma exchange may also have a role </plain></SENT>
<SENT sid="4" pm="."><plain>The overall mortality of CAPS is roughly 50%, but prompt clinical recognition of this rare but devastating syndrome may lead to improved outcomes </plain></SENT>
</text></document>